Nicolai Skovbjerg Arildsen
Ekstern, Ekstern

Brunak Group

Brunak Group
Postaddresse:
Blegdamsvej 3B
2200
København N.
Postaddresse:
Blegdamsvej 3B
2200
København N
E-mail: nicolai.arildsen@cpr.ku.dk
Telefon: +4535330935
Hjemmeside: https://www.cpr.ku.dk/

Kort præsentation

Nicolai began his academic career with his MSc in Molecular Biomedicine from Copenhagen University under the supervision of Torben Gjetting from the CBIO group at DTU Nanotech. The focus of his master's project was drug delivery by lipid nanoparticles in *in vitro* and *in vivo* systems.
Nicolai went on to complete his PhD in March 2019 at the Medical Faculty at Lund University, Sweden. He worked in the Breast and Ovarian Cancer Genomics group of associate professor Ingrid Hedenfalk. During this time he began to master the basics of bioinfomatics and programming in life science. His PhD project focused on using *in vitro* models and high-throughut 'omics to investigate ovarian cancer.
In October 2019, Nicolai joined the Leo Foundation Skin Immunology Research Center at the Medical Faculty of University of Copenhagen as a bioinformatics postdoc. His research focus is atopic dermatitis, and Nicolai will work in the gap between clinical and preclinical research, with the aim of uncerovering the underlying biology of atopic dermatitis.

Ansættelse

Ekstern
Brunak Group
Københavns Universitet
København N.
31 dec. 2019 → nu

Ekstern
Brunak Group
Københavns Universitet
København N.
1 jan. 2020 → nu

Postdoc
Skin Immunology Research Center
Københavns Universitet
København N.
1 okt. 2019 → 15 apr. 2022

Publikationer

Cluster analysis identifies six clinical subtypes of hidradenitis suppurativa characterised by distinct comorbidities, inflammatory and metabolic profiles, patient-reported outcomes and treatment patterns
Jørgensen, A. H. R., Arildsen, Nicolai Skovbjerg, Yao, Y., Holm, J. G., Nielsen, V. W., Ring, H. C., Woetmann, Anders & Thomsen, Simon Francis, 2023, I: JEADV Clinical Practice. 2, 1, s. 80-91

Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three months prospective study
Noshela Ghazanfar, M., Bartko, E. A., Arildsen, Nicolai Skovbjerg, Poulsen, Lars K., Jensen, B. M., Enevold, C., Holm, J. G., Woetmann, Anders , Ødum, Niels & Thomsen, Simon Francis, 2022, I: Clinical and Experimental Allergy. 52, 4 s.

Reduced vitamin D-induced cathelicidin production and killing of Mycobacterium tuberculosis in macrophages from a patient with a non-functional vitamin D receptor: A case report
Al-Jaberi, F. A. H., Crone, C. G., Lindenstrøm, T., Arildsen, Nicolai Skovbjerg, Lindeløv, E. S., Aagaard, L., Gravesen, E., Mortensen, R., Andersen, A. B., Ølgaard, Klaus, Hjaltelin, Jessica Xin, Brunak, Søren, Bonefeld, Charlotte Menne, Kongsbak-Wismann, Martin & Geisler, Carsten, 2022, I: Frontiers in Immunology. 13, 9 s., 1038960.

Epidermal biomarker levels differentiate lesional from non-lesional skin and show variation across anatomical locations in patients with atopic dermatitis
Holm, J. G., Clausen, M., Agner, Tove, Arildsen, Nicolai Skovbjerg, Jakasa, I., Kezic, S. & Thomsen, Simon Francis, 2021 , I: Journal of the European Academy of Dermatology and Venereology : JEADV. 35, 5, s. e325-e327

PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
Martin de la Fuente, L., Westbom-Fremer, S., Arildsen, Nicolai Skovbjerg, Hartman, L., Malander, S., Kannisto, P., Måsbäck, A. & Hedenfalk, I., 2020, I: Virchows Archiv. 477, s. 83–9

Simvastatin is a potential candidate drug in ovarian clear cell carcinomas
Arildsen, Nicolai Skovbjerg & Hedenfalk, I., 2020, I: OncoTarget. 11, 40, s. 3660-3674 15 s.

Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method
Arildsen, Nicolai Skovbjerg, Martin de la Fuente, L., Måsbäck, A., Malander, S., Forslund, O., Kannisto, P. & Hedenfalk, I., 29 okt. 2019, I: Scientific Reports. 9, 1, s. 15506

PD-1/PD-L1 EXPRESSION AND TUMOR-INFILTRATING LYMPHOCYTES ARE PROGNOSTICALLY FAVORABLE IN HIGH-GRADE SEROUS OVARIAN CANCER
de la Fuente, L. M., Fremer, S. W., Arildsen, Nicolai Skovbjerg, Hartman, L., Malander, S., Kannisto, P., Masback, A. & Hedenfalk, I., sep. 2018, s. 761-761.

Targeting Rho GTPases in ovarian clear cell cancer
Arildsen, Nicolai Skovbjerg & Hedenfalk, I., jul. 2018.

Involvement of Chromatin Remodeling Genes and the Rho GTPases *RhoB* and *CDC42* in Ovarian Clear Cell Carcinoma
Arildsen, Nicolai Skovbjerg, Jönsson, J., Bartuma, K., Ebbesson, A., Westbom-Fremer, S., Måsbäck, A., Malander, S., Nilbert, Mef Christina & Hedenfalk, I. A., 2017, I: Frontiers in Oncology. 7, 11 s., 109.

Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival
Jönsson, J., Arildsen, Nicolai Skovbjerg, Malander, S., Måsbäck, A., Hartman, L., Nilbert, Mef Christina & Hedenfalk, I., okt. 2015, I: Translational Oncology. 8, 5, s. 424-33 10 s.

In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection
Gjetting, T., Arildsen, Nicolai Skovbjerg, Christensen, C. L., Poulsen, T. T., Roth, J. A., Handlos, V. N. & Poulsen, H. S., 9 aug. 2010, I: International Journal of Nanomedicine. 5, s. 371-83 13 s.